Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication

• Published in: Alimentary pharmacology & therapeutics Vol. 16; no. 3; pp. 527 - 532
• Main Authors: Di Caro, S., Ojetti, V., Zocco, M. A., Cremonini, F., Bartolozzi, F., Candelli, M., Lupascu, A., Nista, E. C., Cammarota, G., Gasbarrini, A.
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01.03.2002; Blackwell
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Aza Compounds; Biological and medical sciences; Clarithromycin - adverse effects; Clarithromycin - therapeutic use; Drug Combinations; Female; Fluoroquinolones; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Lansoprazole; Male; Medical sciences; Middle Aged; Moxifloxacin; Omeprazole - adverse effects; Omeprazole - analogs & derivatives; Omeprazole - therapeutic use; Patient Compliance; Pharmacology. Drug treatments; Quinolines; Treatment Outcome; Human; Drug combination; Clarithromycin; Spirillales; Toxicity; Spirillaceae; Moxifloxacin; Eradication; Macrolide; Biological activity; Chemotherapy; Fluoroquinolone derivatives; Randomization; Treatment; Helicobacter pylori; Benzimidazole derivatives; Antisecretory agent; Bacteria; Drug interaction; Antibacterial agent; Lansoprazole; Quinolone derivatives
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1046/j.1365-2036.2002.01165.x

Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.